Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 1 1

Status

Recruiting 3Active not recruiting 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

NET 5Endocrine 5Gastrointestinal 2Sarcoma 1Lymphoid 1CNS 1

Conditions

Neuroendocrine Tumors 5Gastro-enteropancreatic neuroendocrine tumor 2Thymus Neoplasms 1Rhabdomyosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Lymphoma 1Central Nervous System Neoplasms 1

Interventions

lutetium Lu 177 dotatate 21Magnetic Resonance Spectroscopy 10pembrolizumab 9Specimen Handling 7Everolimus 7cabozantinib 6Nivolumab 6lenvatinib 5Capecitabine 5177Lu-octreotide, DOTA(0)-Tyr(3)- 5surufatinib 4olaparib 4amino-acid, glucose, and electrolyte solution 4lanreotide 3atezolizumab 3Temozolomide 3Octreotide 3Lutetium-177 3Ipilimumab 3Injections 3Fluorodeoxyglucose F18 3Cyclophosphamide 3gallium Ga 68 dotatate 2fludarabine phosphate 2fludarabine 2avelumab 2X-Rays 2Radiotherapy 2Phantoms, Imaging 2PM 01183 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × 177Lu-octreotide, DOTA(0)-Tyr(3)- × 1 year × Clear all
NCT05918302 2026-05-12

LEVEL

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting
170 enrolled
EndocrineNET

Thymus Neoplasms, Neuroendocrine Tumors

NCT06441331 2026-05-01

KinLET

ITM Solucin GmbH

Phase 1 Recruiting
20 enrolled
CNSEndocrineGastrointestinalLymphoidNETSarcoma

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroendocrine Tumors

NCT03049189 2026-04-06

COMPETE

ITM Solucin GmbH

Phase 3 Active not recruiting
324 enrolled 15 charts
EndocrineNET

Neuroendocrine Tumors

NCT04919226 2025-09-10

COMPOSE

ITM Solucin GmbH

Phase 3 Active not recruiting
259 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT05387603 2025-09-10

START-NET

Lund University Hospital

Phase 3 Recruiting
300 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡